Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15838992 | 1.00 | EZH2 (0.74) | EZH2 | |
| SCHEMBL17305551 | 1.00 | EZH2 (0.74) | EZH2 | |
| SCHEMBL15839135 | 0.94 | EZH2 (0.75) | EZH2 | |
| SCHEMBL15839153 | 0.94 | EZH2 (0.75) | EZH2 | |
| SCHEMBL15839111 | 0.93 | EZH2 (0.70) | EZH2 | |
| SCHEMBL20749674 | 0.92 | EZH2 (0.70) | EZH2 | |
| SCHEMBL15839162 | 0.91 | EZH2 (0.72) | EZH2 | |
| SCHEMBL15839165 | 0.91 | EZH2 (0.72) | EZH2 | |
| SCHEMBL15839168 | 0.91 | EZH2 (0.72) | EZH2 | |
| SCHEMBL15839102 | 0.91 | EZH2 (0.68) | EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | claimed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | claimed |
| EP-2935214-B1 | 1,4-PYRIDONE COMPOUNDS | EPIZYME INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | EZH2 1/4885 |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | PDXK, PNPO, PLPBP | EZH2 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.